In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
213 News Items found
(Left to right) Medical oncologist Mark Robson, gynecologist Noah Kauff, medical oncologist Zsofia Stadler, and Clinical Genetics Service Chief Kenneth Offit are applying genetic insights to improve the care of cancer patients.
Genetic Information Becomes a Vital Part of Clinical Practice

At Memorial Sloan Kettering, as the genetics revolution continues to flourish, discoveries made in the laboratory are increasingly producing real-world benefits for cancer patients.
Dr. Alicia Latham, Dr. Michael Walsh, Dr. Zsofia Stadler, and Megha Ranganathan
Feature
Inherited Cancer Risks: New Insights from MSK Presented at 2023 ASCO Meeting

MSK investigators are leading research focused on understanding how hereditary DNA mutations affect cancer development and therapy, and how to best treat people who carry these inherited risks in their genes.
Michael Postow, Nitya Raj and Triparna Sen
MSK Leaders Recognized in the 40 Under 40 in Cancer Class of 2020

Chief of the Melanoma Service Michael Postow, MD, Medical Oncologist Nitya Raj, MD, and Assistant Attending Triparna Sen, PhD were included on this year’s list.
Joan Massagué leads Memorial Sloan Kettering's Metastasis Research Center
Opening Cancer's Black Box

The Metastasis Research Center has brought together 27 Memorial Sloan Kettering laboratories to facilitate research on metastasis and its treatment.
Bridget Anderson
Fecal Transplants Boost Helpful Microbiota for Stem Cell Transplant Patients

To help some patients to overcome leukemia, MSK doctors are calling upon patients’ microbiomes — the vast ecosystems of microorganisms that live within us, especially the gut. These microbes appear to help some patients recover from bone marrow and stem cell transplants.
Three syringes stuck into an orange and white bull’s-eye
In the Clinic
Drug Targeting Genetic Mutation Works across All Tumor Types

A drug effective in all cancer types with a mutation called a TRK fusion could be the first ever developed simultaneously in adults and children.
Selwyn M. Vickers, MD, FACS
A Message From MSK’s President and CEO, Dr. Selwyn Vickers

In cancer care, firsts make a difference. At MSK, we are constantly improving how we help people with those important firsts. Dr. Selwyn Vickers writes about the latest developments at MSK and the encouraging evidence that we are making progress in our mission of ending cancer for life.
Illustration of human neck and head with thyroid gland highlighted and tumor growing on gland.
Science Byte
Breaking Bad: Researchers Find Mutations that Turn Thyroid Cancers Deadly

MSK researchers identify mutations that convert nonthreatening thyroid tumors into aggressive cancers.
Detail shot of a nurse holding hands with a patient
MSK Research Highlights, May 10, 2024

New MSK research measures unscheduled healthcare interactions in multiple myeloma patients receiving T cell redirection therapies; investigates oral bacteria’s link to gut microbiota depletion with implications for cancer patients; and shows how a universal opt-out approach could help more cancer patients quit smoking.
An MSK researcher at work in the lab
MSK Research Highlights August 31, 2026

New MSK research identifies a tumor-secreted protein that primes the lungs for metastasis; shows how a new drug combination improves survival in patients with advanced clear cell renal cell carcinoma; and find a three-drug combination works in most patients newly diagnosed with follicular lymphoma.